To provide evidence-informed guidance on best practices in the management of patients with HR+/HER2- metastatic breast cancer in Canada, consensus recommendations were developed by Research Excellence, Active Leadership Canadian Breast Cancer Alliance (REAL Alliance), a standing nucleus committee with both clinical-academic oncologists from across Canada and representatives from Breast Cancer Canada, a patient advocacy organization. The gene discussed is ERBB2; the disease is breast carcinoma.